
Journal Review in Breast Surgery: Evolution of DCIS Management
Behind The Knife: The Surgery Podcast
00:00
The Effects of Pembrolizumabylon on the Immune System
Dr. Riven: DCIs are just as heterogeneous as invasive cancer. We don't treat all breast cancers the same. And there are some cancers that are super low risk that don't need much therapy at all either. The reason why they're still DCS is because they have this immune infiltrate.
Transcript
Play full episode